A Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder
Open Access
- 1 February 2025
- journal article
- case report
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (2) , e01618
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a potential life-threatening complication after solid organ transplantation. PTLD can be associated with Epstein-Barr virus through either primary infection or reactivation during treatment with immunosuppressive medications. We present a rare case of Epstein-Barr virus-positive classical Hodgkin lymphoma PTLD following liver transplantation, which was initially misattributed to late transplant rejection and raised concerns for cholangiocarcinoma due to abnormal laboratory and imaging findings.Keywords
This publication has 8 references indexed in Scilit:
- NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022Journal of the National Comprehensive Cancer Network, 2022
- Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypesLeukemia & Lymphoma, 2020
- Diffuse Large B-Cell Lymphoma in the Portal VeinJournal of the Korean Society of Radiology, 2020
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Hodgkin lymphoma post‐transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survivalAmerican Journal of Hematology, 2016
- Post-transplant Lymphoproliferative Disorders2015
- Managing the challenge of PTLD in liver and bowel transplant recipientsBritish Journal of Haematology, 2014
- Treatment of PTLD with Rituximab or ChemotherapyAmerican Journal of Transplantation, 2006